Table 1 Summarised cohort/stratified baseline characteristics of patients receiving biologic drugs, analysed for CD11c expression by qPCR

Gender, female, n (%)

27 (79.4 %)

31 (75.6 %)

0.695^a

20 (80 %)

20 (80 %)

1.00^a

7 (77.8 %)

11 (68.8 %)

0.629^a

Age, baseline, years, mean (SD)

59.3 (12.3)

53.3 (10.3)

0.023^b

61.2 (12.2)

54.86 (11.4)

0.065^b

54.3 (11.7)

50.7 (8.2)

0.258^b

Concurrent DMARDs, n (%)

28 (82.4 %)

36 (90 %)

0.338^a

22 (88 %)

21 (84 %)

0.684^a

6 (66.7 %)

15 (100 %)

0.017^a

Baseline DAS28, median (IQR)

6.2 (5.4–6.6)

5.8 (5.5–6.3)

0.131^c

6.2 (5.8–6.6)

5.9 (5.5–6.2)

0.156^c

6.6 (5.6–7.03)

5.6 (5.3–6)

0.101^c

3 month DAS28, median (IQR)

5.65 (5.4–6.2)

2.15 (1.6–2.5)

<0.001^c

5.6 (5.3–5.9)

2.3 (1.9–3)

<0.001^c

6.6 (5.3–6.8)

1.95 (1.6–2.2)

<0.001^c

Baseline TJC, median (IQR)

16 (10–19)

13 (10–16)

0.205^c

14 (10–18)

13 (10–15)

0.515^c

18 (16–24)

13 (10–19)

0.157^c

Baseline SJC, median (IQR)

8.5 (4–13)

9 (6–13)

0.701^c

7 (4–11)

9 (6–13)

0.268^c

11 (9–15)

8.5 (6–13)

0.211^c

Baseline ESR, median (IQR), n

33 (14–44), 26

18 (14–33), 35

0.11^c

32 (23–41), 21

18 (10–34), 23

0.158^c

34 (10–60), 5

20.5 (14–31), 12

0.712^c

Baseline HAQ, median (IQR), n

2.06 (1.38–2.3), 22

1.5 (1.13–2), 32

0.026^c

2.1 (1.9–2.3), 17

1.4 (1.1–1.6), 19

0.006^c

1.9 (1.3–2.1), 5

1.8 (1.1–2.4), 13

0.96^c

Tempus™ Blood Tube, n (%)

21 (61.8 %)

22 (53.4 %)

0.48^a

15 (60 %)

14 (56 %)

0.774^a

6 (66.67 %)

8 (50 %)

0.420^a